



23 August 2021

Company Announcements Office
Australian Securities Exchange

VECTUS SUCCESSFULLY COMPLETES THE FIRST GROUP IN PHASE I HUMAN TRIAL

Vectus Biosystems Limited (Vectus or the Company) is pleased to announce that the first cohort consisting of eight subjects has completed all protocol requirements for the 2mg dose in the Single Ascending Dose (SAD) component of its Phase I/IB trial entitled:

“A phase I/IIb, first-time-in-human, single centre, double blind, randomised, placebo-controlled, dose-escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of VB0004 administered orally to healthy volunteers; and to patients with mild to moderate hypertension with low cardiovascular risk”.

The results for this cohort have been reviewed by the trial safety committee and it has been deemed safe to proceed with the next dosage level.

Dr Ron Shnier said “this is an important milestone in progressing our human Phase I/IB trials of the VB004 Cardiovascular Lead. Fibrosis underpins a broad spectrum of cardiovascular disease and Vectus is targeting its reversal”.

The trial is registered on the Clinical Trials Protocol Registration and Results Systems (ClinicalTrials.gov) and has been provided with the identifier NCT04925050. Protocol details may be found using this number on the ClinicalTrials.gov public website.

Vectus Biosystems Limited

Karen Duggan

Chief Executive Officer and Executive Director

This Vectus announcement was authorised by the Board of Directors.



About Vectus Biosystems Limited

Vectus Biosystems Limited is developing a treatment for fibrosis and high blood pressure, which includes the treatment for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Vectus successfully completed its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX:VBS) and commenced trading on ASX on 23 February 2016, after raising A\$5.1 million. Funds from the IPO were predominantly used to develop the Company's lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 is now progressing through a number of important milestones, including pharmaceutical scale-up and additional toxicity studies. Following successful results, the late 2019 convertible note fundraising, and the late 2020 share placement, the Company has funding for its Human Phase I trial. Vectus' strategy is to develop and perform early validation of its drug candidates to the point where they may become commercially attractive to potential pharmaceutical partners.

The Company has also developed technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The technology, called Accugen, is owned by Vectus' wholly-owned subsidiary Accugen Pty Limited. The technology offers a time, cost and accuracy benefit compared to currently-available systems. The Company's current stage of investment in Accugen is a commercialisation programme that may include direct sales, distribution partnerships and licensing opportunities.